Boletín de inteligencia clínica

Nine cancer cases have been reported in Zolgensma recipients, with two showing evidence that the viral delivery vector integrated into patient DNA. The disclosure raises new questions about gene therapy safety and the potential for long-term oncogenic risks from viral vector integration.

Regulators finalized a rule slashing payments for drugs in the 340B program while equalizing payments between different care sites starting in 2027. Hospitals strongly opposed the rule, which represents a significant shift in Medicare reimbursement policy.

Third-quarter sales for Novo's oral Wegovy pill came in well above consensus estimates, extending the company's early lead over Eli Lilly in the oral weight loss drug market. The strong performance provides a much-needed boost for Novo amid intensifying competition.

The agreement marks a strategic shift for Hims, which had previously sold compounded knockoff GLP-1 drugs. The deal formalizes the telehealth company's entry into the branded GLP-1 market alongside Eli Lilly.

The pancreatic cancer drug Rasonque is tracking ahead of all previous cancer drug launches, prompting Wall Street analysts to revise sales projections upward. Company executives cautioned that it remains too early to draw definitive conclusions about the launch trajectory.

Johnson & Johnson and AbbVie will present early data on three-pronged antibody therapies for multiple myeloma at the upcoming ASH conference. The trispecific antibodies represent a potential advancement beyond current bispecific approaches in blood cancer treatment.

The startup raised a megaround to advance technology designed to target previously undruggable cancer targets and develop selective autoimmune disease treatments. The platform focuses on bispecific antibodies with enhanced selectivity profiles.

The startup is developing treatments for myeloproliferative neoplasms, with investors claiming its lead candidate could have broader applicability than currently approved drugs. The Series A financing will support clinical development of the rare blood cancer portfolio.

The decision to halt development of the immune drug for eczema triggered a sell-off in Nurix shares and sparked analyst debate about the viability of STAT6-targeting protein degraders. The setback raises questions about the druggability of the STAT6 protein target.